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Abstract
Recently, we described a new animal model of CNS primitive neuroectodermal tumors
(CNS-PNET), which was generated by orthotopic transplantation of human Radial Glial
(RG) cells into NOD-SCID mice’s brain sub-ventricular zone. In the current study we con-
ducted comprehensive RNA-Seq analyses to gain insights on the mechanisms underlying
tumorigenesis in this mouse model of CNS-PNET. Here we show that the RNA-Seq profiles
derived from these tumors cluster with those reported for patients’ PNETs. Moreover, we
found that (i) stabilization of HIF-1α and HIF-2α, which are involved in mediation of the hyp-
oxic responses in the majority of cell types, (ii) up-regulation of MYCC, a key onco-protein
whose dysregulation occurs in ~70% of human tumors, and (iii) accumulation of stabilized
p53, which is commonly altered in human cancers, constitute hallmarks of our tumor model,
and might represent the basis for CNS-PNET tumorigenesis in this model. We discuss the
possibility that these three events might be interconnected. These results indicate that our
model may prove invaluable to uncover the molecular events leading to MYCC and TP53
alterations, which would be of broader interest considering their relevance to many human
malignancies. Lastly, this mouse model might prove useful for drug screening targeting
MYCC and related members of its protein interaction network.
Introduction
Embryonal tumors of the central nervous system (CNS) are part of a heterogeneous group of
tumors with controversial morphology-based diagnosis, and largely unknown origin [1]. They
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represent 33% of brain tumors, and affect mainly infants and children younger than 3 years.
The group includes (i) medulloblastomas, which arise in the cerebellum, (ii) CNS primitive neu-
roectodermal tumors (CNS-PNET), which occur in the cerebral hemispheres, in the brain stem
and spinal cord, and include CNS neuroblastomas, CNS ganglioneuroblastomas, medulloe-
pitheliomas and ependymoblastomas, and (iii) atypical teratoid rhabdoid tumors (AT/RT) [2].
In this manuscript, supratentorial PNET is referred to as CNS-PNET according to the 2007
WHO CNS tumor classification criteria (ICD-O 9473/3, WHO grade IV). CNS-PNET arises
from primitive neuroepithelial cells, and occurs predominantly in children and adolescents.
These tumors remain largely refractory to currently available modalities of therapy [2, 3]. His-
tologically, CNS-PNET is composed mainly of undifferentiated or poorly differentiated neu-
roepithelial cells with variable amounts of components of divergent differentiation along
neural, ependymal and astrocytic lines [2].
Recent molecular studies of large cohorts of embryonal tumors have shed some light to
their biology. An integrative genomic analysis of CNS-PNET has categorized these tumors
into three distinct subgroups: primitive-neural (group 1), oligo-neural (group 2), and mesen-
chymal (group 3) [4]. The primitive-neural subgroup often exhibits a younger age of onset
(4 years) and a higher prevalence in female patients. It has the worst prognosis among all
three subgroups. On the other hand, patients with tumors of the mesenchymal subtype present
with the highest incidence of metastases at the time of diagnosis [4]. Recently, methylation and
gene expression analyses performed for another large series of tumors showed a significant
overlap of CNS-PNET with a variety of other pediatric brain tumor types, including high-
grade glioma, medulloblastoma and ependymoma [5]. Yet another CNS-PNET study revealed
that MYCN or MYCC gene amplifications were present in about half of the cases examined,
which was correlated with decreased survival [6]. The above mentioned studies underscore the
value of molecular stratification for improved diagnosis and treatment of CNS-PNETs.
Unfortunately, these studies are limited in scope due to multiple factors, including availabil-
ity of a sufficient number of specimens, tumor heterogeneity, surgical accessibility depending
upon tumor location etc. Hence, the development of new animal models of CNS-PNETs is
necessary [7] to enable advancement in the field.
Recently, we described an animal model of CNS-PNET that was generated by orthotopic
transplantation of human Radial Glial (RG) cells into NOD-SCID mice’s brain sub- ventricular
zone [8]. In the current study we explore our CNS-PNET animal model further to get new
insights into the onset of tumor formation, and we put forth the hypothesis that hypoxia might
play a pivotal role in the development of these tumors.
Materials and methods
Ethics statement
All animal-related procedures were approved by the Stanley Manne Children’s Research Insti-
tutional Animal Care and Use Committee accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care and conformed to the standards of the National
Institutes of Health (IACUC protocol #: 2011–09).
Orthotopic transplantation of RG cells to the Sub-Ventricular Zone (SVZ)
of the 3rd ventricle in NOD-SCID mice brain
Transplantations of the LC25-R, LC26-R, and LCAS-R RG cells to the SVZ of 3rd ventricle of
the brain of NOD-SCID mice (in average ten mice per each RG cell line) were performed as
previously described [8]. Derivation of these RG lines was described previously [8]. Briefly,
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transplantations of RG cells to target SVZ of 3rd ventricle were performed as follows: a 1.0mm
burr hole was made approximately 0.3mm dorsal caudal from the bregma. A 26-gauge needle
attached to a 25 μl Hamilton syringe was inserted into the depth of 4.0mm from the skull sur-
face using stereotactic guidance. Five microliters containing ~100,000 of the RG cells were inoc-
ulated into the brain over a period of 10 minutes. The respiratory rate and the anesthetic depth
of all animals were monitored every 5 minutes after the surgery by laboratory personnel until
the animals had fully recovered from the anesthesia. No adverse events were encountered dur-
ing the post-operative care. All mice were kept in standard animal husbandry with regular diet
in barrier facilities and monitored 2–3 times per week, including recording of their body weight.
The mice were sacrificed at 4–8 weeks post-inoculation by an i.p. injection of Nembutal Sodium
40–70 mg/kg followed by cervical dislocation, at which time brains were harvested and tumors
were resected. The tumor tissues were named LC25-RT, LC26-RT, and LCAS-RT, respectively.
Total RNA isolation
Total RNA isolation from tumor tissues was performed with the PureZOL RNA isolation
reagent (Bio-Rad, Hercules, CA), followed by DNAse treatment (Ambion, Austin, TX),
according to the manufacturer’s instructions. Purity and integrity of the isolated RNA was
assessed on the ND-1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA).
RNA-seq and data analysis
RNA-Seq library construction was performed according to the manufacturer’s instructions for
RiboZero selection. The resulting libraries were sequenced using Illumina HiSeq2500. The
FastQC software (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) was applied on
raw fastq files to examine the sequence quality. Tophat [9] was used for tag alignment and
counts for each gene were computed by means of HTSeq Python package [10], using the anno-
tation of the Ensembl genes and only reads that mapped to exons.
Differential expression analysis on the count data was performed using DESeq2 [11], which
is based on a negative binomial distribution and uses shrinkage estimation for the variance of
the distribution. As an alternative way of quantifying normalized gene and transcript expres-
sion, Fragments Per Kilobase of transcript per Million mapped reads (FPKM) values were also
derived using Cufflinks [12] and were furthered normalized by upper quartile normalization
(GEO record GSE82102).
The hierarchical clustering was performed using R (function heatmap.2 in “gplots” pack-
age). Public RNA-seq data: 10 TCGA GBM and 10 LGG paired-end RNA-seq raw fastq files
were downloaded from https://cghub.ucsc.edu/cghub/data/analysis/download. 10 PNET
RNA-seq samples were downloaded from SRA archive (SRP032476). All these publicly down-
loaded samples were analyzed using the same pipeline as for our own samples.
Single nucleotide variant (SNV) and small Indel calling were conducted for both RG and
tumor samples. Alignment files generated by Tophat2 were used for SNV detection using
SAMtools [13] and Varscan [14] with the following parameters: map quality>15, PHRED
quality score>10, coverage>8 reads, P value threshold for calling variant = 0.01 and minimum
supporting reads at a position to call variant = 2. We used ANNOVAR [15] for annotation of
the called variants and SAMtools view was used to visualize the aligned reads in the region of
TP53.
Real-time PCR
Total RNA isolation was performed as mentioned above. cDNA synthesis and real-time quan-
titative reverse transcription-polymerase chain reactions (qRT-PCR) were performed as
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previously described [16]. QuantStudio 7 instrument (Applied Biosystems, USA) along with
PowerUP SYBR Green Master Mix (A25742, Fisher) were used according to the manufac-
turer’s instructions. The PCR conditions were as follows: one cycle at 50˚C for 2 min, one
cycle at 95˚C for 10 min, 40 cycles at 95˚C for 15 s, 60˚C for 1 min, followed by a melting
curve from 60˚C to 95˚C. Primers were designed using the Primer Express program version
1.5 (Applied Biosystems, CA, USA), and obtained from Integrated DNA Technologies (Coral-







100 nM primers for GUSB RNA (RealTimePrimers.com) were used as an endogenous con-
trol for each of the cDNA samples. Comparative Ct method was used to analyze the qRT-PCR.
In the comparative Cm method the QuantStudio 7 software measures amplification of the gene
of interest (target) and of GUSB in each cDNA sample. Measurements are normalized using the
endogenous control. The software determines the relative quantity (RQ) of target in each sam-
ple by comparing normalized target levels in each sample (LC25-RT, LC26-RT, or LCAS-RT) to
normalized target quantity in the reference sample (LC25-R, LC26-R, or LCAS-R).
Immunohistochemistry
Formalin-fixed paraffin embedded (FFPE) tumor tissue and RG cell pellets generated in our
previously published study [8] were used for histological and immunohistochemical analyses.
At least two slides (5μm thick) from each FFPE tumor sample were used for the analysis of
each antibody presented in this study using standard immunohistochemical methods (see S2
Table).The immunohistochemical panel comprised the following antibodies: Anti-Ki-67 (RM-
9106, Rabbit monoclonal, 1:200, Thermo scientific), POU5F1/OCT3/4 (LS-B85, Rabbit poly-
clonal, 1:300, LSBio), Anti-Nestin (ab105389, Rabbit monoclonal, 1:30, abcam), Anti- Sox2
(ab97959, Rabbit polyclonal, 1:200, abcam), Anti-Vimentin (NBP1-97671, Mouse monoclonal,
1:500, Novus Biologicals), Anti-c-MYC (ab32072, Rabbit monoclonal[Y69], 1:500, abcam),
Anti-c-MYC-(Phospho S62) (ab185656, Rabbit monoclonal, 1:500, abcam), Anti-MAX
(ab101271, Rabbit polyclonal, 1:1000, abcam), Anti-HIF-1α (ab82832, Rabbit polyclonal,
1:100, abcam), Anti-HIF-2α (ab73895, Rabbit polyclonal, 1:250, abcam), Anti-p53 (LS-B7722,
Rabbit polyclonal, 1:200, LSBio), Anti-YB1 (ab12148, Rabbit polyclonal, 1:750, abcam), Anti-
MDM2 (LS-C199239, Rabbit polyclonal, 1:100, LS Bio).
RG cell culturing under hypoxic conditions
RG cells were cultured for 24 days under the same conditions, except for the concentration of
O2, which was either alternated hypoxic (16 days—5% O2, 4 days—20% O2, 4 days—5% O2) or
normoxic (20% O2). LC26-10R is one of the clones of the LC26-R cell line.
Western blotting
Whole cell lysates were prepared using M-PER™ Mammalian Protein Extraction Reagent plus
protease and phosphatase inhibitors (Thermo Scientific, Rockford, IL). After centrifugation at
13K rpm for 15 minutes at 4˚C, the protein concentration of the supernatant was determined
using a Pierce™ 660nm Protein Assay Kit (Thermo Scientific, Rockford, IL) and 40μg of total
protein loaded per well of a Novex 4–12% NuPAGE Bis-Tris gel (Life Technologies, Carlsbad,
CA). After electrophoresis, the proteins were transblotted onto a nitrocellulose blotting
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membrane (Bio-Rad Laboratories, Hercules, CA) and the proteins detected using Anti-HIF-
2α (ab73895, Rabbit polyclonal, 1:250, abcam), Anti-POU5F1/OCT3/4 (LS-B85, Rabbit poly-
clonal, 1:300, LSBio), Anti- c-MYC-(Phospho S62) (ab185656, Rabbit monoclonal, 1:500,
abcam), Anti- Sox2 (ab97959, Rabbit polyclonal, 1:200, abcam), goat anti-rabbit antibody
linked to horseradish peroxidase (sc2030 Santa Cruz, Dallas, TX) and ECL substrate (Western
Bright ECL, Advansta,Menlo Park, CA). The blot was then stripped and probed for GAPDH
or Beta-actin protein using a mouse monoclonal antibody (GAPDH: SC365062, Santa Cruz,
Dallas, TX, Beta-actin: MA5-15739, ThermoFisher Scientific, Waltham, MA), goat anti-mouse
antibody linked to horseradish peroxidase (sc2005 Santa Cruz, Dallas, TX) and ECL substrate.
Protein levels were estimated by densitometry using ImageJ software and the differences in
HIF-2a, Oct3/4, c-MYC-(Phospho S62) and Sox2 proteins calculated after correcting for pro-
tein loaded per lane using the GAPDH or Beta-actin protein control.
Results
RNA-Seq profiles of tumors from the CNS-PNET animal model cluster
with those derived from patients’ CNS-PNETs
Histopathological analyses of the tumors from our model revealed hallmarks of neuroectoder-
mal origin that are characteristic of CNS PNET [8]. We sought to validate this observation by
applying unsupervised hierarchical clustering of RNA-seq data from three of our CNS-PNET
model tumors (LC25-RT, LC26-RT, and LCAS-RT) along with ten CNS-PNETs, ten glioblas-
tomas (GBM) and ten low-grade gliomas (LGG), from publicly available RNA-seq data (see
Materials and Methods). We also applied a supervised hierarchical clustering analysis of the
same dataset using a list of 225 TFs and receptors, which are consistently expressed in our
tumors at intermediate or high levels (similar to or higher than the average level of expression
observed for house-keeping genes; S1 Table). Additionally, we used a list of genes that have
been identified as predictive markers of PNET according to Picard’s molecular classification
[4]. Based on the unsupervised hierarchical clustering analysis, our tumors clustered with the
CNS-PNET group (S1 Fig). Applying Picard’s molecular signature, our tumors clustered with
the mesenchymal and oligo-neural subtypes of CNS-PNET (Fig 1). Interestingly, the clustering
analysis of TFs and receptors revealed that our tumors are closest to the primitive-neural sub-
group of CNS-PNETs (samples 1, 2, 3, 7, 8, 9; see Fig 1 and Fig 2).
The CNS-PNET model tumors are enriched with markers of NSC self-
renewal
There is evidence that brain tumorigenesis can be driven by alterations occurring in neural
stem cells (NSCs) that render them transformed to brain tumor-initiating cells (BTICs) [17,
18]. In particular, presumably transformed RG cells have been considered to function as puta-
tive BTICs in ependymomas [18]. Histologically, divergent differentiation of CNS-PNET,
which is reflected by variable amounts of neuronal, ependymal, and glial cellular components
within the tumor, may be interpreted as indicative of the presence of both NSCs and BTICs in
these tumors, and that the latter may be responsible for its development [2]. Notwithstanding
all supportive evidence, however, it should be underscored that the presence of cells with
tumor-initiating properties does not necessarily imply causality for tumorigenesis, nor does it
exclude the role of other cells. The existing data simply serve to demonstrate that such tumors
indeed harbor cells that have the capability of initiating tumors.
The initiation of tumors in our CNS-PNET model by orthotopic transplantation of RG cells
suggested the presence of BTICs amidst the RG cell population, which would be responsible
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for the onset of tumor formation. Using our CNS-PNET model, we validated the expression of
the NSC self-renewal markers SOX2 (S1 and S2 Tables, Fig 3E and 3F), Nestin, and Vimentin,
which are also considered as BTIC markers [8, 16, 17, 19–23], including in CNS-PNET [7, 24]
(S2 Table, Fig 3C, 3D, 3G and 3H). Remarkably, Oct3/4 (POU5F1), which was recently
described as a new BTIC marker [19], is also expressed in our tumor model (Fig 3B, S1 and S2
Tables). It is conceivable that, in our model, the expression of markers associated with self-
Fig 1. Supervised hierarchical clustering analysis of our CNS-PNET model tumors (molecular markers). List of molecular
markers of CNS -PNET according to Picard’s classification. Gene symbol_1—primitive-neural (group 1) marker, Gene symbol_2—
oligo-neural (group 2) marker, Gene sybmol_3—mesenchymal (group 3) marker.
doi:10.1371/journal.pone.0173106.g001
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renewal of NSC/BTIC in tumor cells might be responsible for maintenance of the primitive
neuroectodermal phenotype [8]. It is also noteworthy that the presence of these markers in the
majority of the tumor cells (Fig 3, S2 Table) correlates with the rapid progression to large,
aggressively disseminating undifferentiated tumors documented in our model [8]. However,
as aforementioned, the mere presence of these markers cannot be deemed sufficient to render
them functional BTICs. Such possibility will be the subject of future investigation.
HIF-1α and 2α stabilization, up-regulation of OCT3/4 and MYCC provide
a plausible mechanism for tumorigenesis in our CNS-PNET model
We hypothesize that hypoxia is one of the micro-environmental factors involved in the onset of
tumorigenesis in our model [8], as it is a critical component of stem cell niche function, keeping
the undifferentiated phenotype of stem/precursor cells [25, 26]. Since our RG cells represent the
early stages of primitive neuro-ectoderm differentiation [16], and the stem cells that normally
reside in the 3rd sub-ventricular zone correspond to adult NSCs, it is conceivable that while pro-
tective for the adult NSC, hypoxia might trigger tumorigenesis of the orthotopically trans-
planted RG cells that are at a significantly earlier stage in ontogenesis. Low oxygen level could
lead to stabilization of HIF-1α and 2α in parental RG cells. This, in turn, would activate BTIC
marker OCT3/4, a direct target of HIF-2 α, along with BTIC marker SOX2, and the critical plu-
ripotent stem cell inducer–MYCC, an onco-protein whose increased expression plays a central
role in multiple aspects of tumor cell biology [25–32]. Interestingly, HIF-1 α, which is involved
Fig 2. Supervised hierarchical clustering analysis of our CNS-PNET model tumors (transcription factors and
receptors). List of the 225 transcription factors and receptors (S1 Table), which are consistently expressed in our tumors at
intermediate or high level of expression (similar or higher than average house-keeping gene expression level).
doi:10.1371/journal.pone.0173106.g002
Fig 3. BTIC markers in our CNS-PNET model tumors. A: Ki67, 20X, insert- 5X digital (LCAS-R-12 weeks post-injection) B: Oct3/4, 40x, insert- 5X digital
(LCAS-R-12 weeks post-injection) C: Nestin 20x, insert- 5X digital (LCAS-R-12 weeks post-injection) D: Nestin 40x, insert- 5X digital (LCAS-R-12 weeks
post-injection) E: Sox2 40X, insert- 5X digital, (LC26-R-12 weeks post-injection) F: Sox2 40X, insert- 5X digital (LCAS-R-12 weeks post-injection) G: Vimentin
5X, insert- 5X digital (LCAS-R-12 weeks post-injection) H: Vimentin 20X, insert- 5X digital (LC26-R-12 weeks post-injection) TU-tumor; P-parenchyma;
V-ventricle; CP-choroid plexus.
doi:10.1371/journal.pone.0173106.g003
Hallmarks of CNS-PNET animal model
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in mediation of the hypoxic responses in the majority of cell types, is expressed in our tumor
model along with SOX2 and OCT3/4 (S1 Table). Therefore, we reason that altogether, these
events could provide a plausible mechanism for tumorigenesis in our model.
To begin to investigate our hypothesis we tested if HIF-1 α and HIF-2 α proteins, which are
known to be degraded in normoxic conditions [33], are expressed in the tumor cells. Indeed,
immunostaining revealed that the majority of tumor cells exhibit nuclear expression of HIF-1
α and HIF-2 α (Fig 4E–4H, S2 Table), along with SOX2 and OCT3/4, as stated above.
Remarkably, we also found MYCC as being highly expressed in our tumors (Fig 4A, S1 and
S2 Tables). In adult tissues, MYCC expression is usually low and restricted to cells with prolif-
erative potential [34]. To activate or repress transcription consistently, MYCC has to be stabi-
lized by phosphorylation at the N-terminus of Ser 62, which is known to protect the MYC
protein from proteasomal degradation [35]. The stabilized form of MYCC is also highly
expressed in our tumors (Fig 4B, S2 Table). Moreover, MYCC has to heterodimerize with a
partner protein, MYC-associated protein X (MAX) [36], which is also abundantly expressed in
our model (Fig 4C and 4D, S1 and S2 Tables).
Next, we tested the response of the RG cells to a prolonged exposure to low oxygen condi-
tions, monitoring the expression level of HIF-2 α, OCT3/4, SOX2, and c-MYC-(Phospho S62)
by western blot, using GAPDH or Beta-actin proteins as endogenous controls. Consistent with
the aforementioned hypothesis, all these proteins were up-regulated after exposure to hypoxia
(Fig 5, S2 Fig).
Accumulation of stabilized p53 is observed in our CNS-PNET tumor model
Hypoxic microenvironment has been implicated in genetic instability [37, 38]. It increases the
frequency of mutations in cell culture as well as in animal tumor models [39]. Consequently,
Fig 4. cMYC, c-MYC-(Phospho S62), HIF-1α, HIF-2α in our CNS-PNET model tumors. A: cMYC 40X, insert- 5X digital (LCAS-R-12 weeks post-injection)
B: c-MYC-(Phospho S62) 20X, insert- 5X digital (LCAS-R-12 weeks post-injection) C: MAX 40X, insert- 5X digital (LCAS-R-12 weeks post-injection) D: MAX
20X (LCAS-R-12 weeks post-injection) E: HIF-1α 40X, insert- 5X digital (LCAS-R-12 weeks post-injection) F: HIF-1α 20X, insert- 5X digital (LCAS-R-12
weeks post-injection) G: HIF-2α 5X, insert- 5X digital (LCAS-R-12 weeks post-injection) H: HIF-2α 40X, insert- 5X digital (LCAS-R-12 weeks post-injection)
TU-tumor; P-parenchyma; V-ventricle; N-necrosis.
doi:10.1371/journal.pone.0173106.g004
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hypoxia could inactivate the function of the key tumor-suppressor gene TP53, which would
reduce hypoxia-induced cell death and allow the survival of cells with cumulative DNA dam-
age [40]. Mutations of the TP53 gene are detected in many different types of human cancer
[41–43], with the majority of them being missense mutations within the DNA-binding core
domain [44]. However, the pathways responsible for these molecular alterations have yet to be
identified.
Remarkably, p53 is overexpressed in our model (Fig 6B and 6C, S1 and S2 Tables) with
more than 90% of tumor cells showing nuclear expression of the protein. In contrast, it is
expressed in less than 10% of the parental RG cells (Fig 6A). This pattern of p53 immunoex-
pression in the tumors is indicative of the presence of mutant p53 protein. As wild-type p53
protein is relatively unstable it is virtually undetectable by immunohistochemistry, while
the mutant p53 becomes stabilized, and accumulates in the nucleus, thereby making its detec-
tion by immunohistochemistry possible [45]. Surprisingly, comparative sequence analysis of
RNA-Seq data derived from TP53 in the parental RG and tumor cells in our model did not
reveal any SNVs or indels (data not shown, see Material and Methods). It is conceivable, how-
ever, that the documented stabilization of p53 might be due to an aberrant posttranslational
modification, which is known to suppress p53 functional activities, including growth arrest
and transcriptional activation of target genes [46], as the stabilization of p53 is depicted in
actively invading tumor cells (Fig 6B and 6C digital inserts). Notably, we found the transcrip-
tion factor YB1 being expressed at high levels in our tumor model (Fig 6D, S1 and S2 Tables).
YB1 expression in the cytoplasm of tumor cells is consistent with the functional inactivation of
TP53, as nuclear translocation of YB1 would require expression of wild-type p53 [47, 48]. YB1
is an essential marker of tumorigenesis as its expression significantly correlates with tumor
stage and patient prognosis for many human tumors, including glioblastoma and medulloblas-
toma [49–53]. The aberrant modification of p53 protein might also render resistance to
MDM2 mediated degradation [46], despite the elevated level of MDM2 in the tumor tissue
(Fig 6E and 6F, S2 Table). MDM2 is involved in ubiquitination and proteasome degradation
of wild-type p53 protein, and considered as one of the key regulators of p53 stability [46]. Of
note, the mRNA level of TP53 is reduced in the tumor (S3A Fig), along with the mRNA level
of P21 (S3B Fig)–a direct target of active p53 [48], which might indicate the functional integ-
rity of MDM2 as it is known to block TP53 transcription [54, 55]. Nevertheless, at this point
Fig 5. Western blot. Protein quantitative difference between the RG cells grown for 24 days in normoxic versus hypoxic conditions. The quantitative
differences of the proteins calculated after the correction for actual protein loaded per lane using the GAPDH protein control.
doi:10.1371/journal.pone.0173106.g005
Hallmarks of CNS-PNET animal model
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we can’t unequivocally prove the functional inactivation of the stabilized p53, which will be the
subject of a follow up study.
Discussion
As PNET transcriptome profiles from recent studies exhibit a significant overlap with those
observed for a number of brain tumor types [5], it is conceivable that cell origin or onset of
tumorigenesis are also shared in these tumors, which make our model potentially relevant to a
broad range of brain tumors, including a variety of embryonal tumors, beyond CNS-PNET.
The fact that tumors in our model can be consistently generated in only 4–8 weeks, rapidly
progressing to large, aggressively disseminating tumors point to the robustness of the molecular
mechanisms underlying tumorigenesis in our model. Such a behavior may suggest the occur-
rence of rather few discrete alterations of major functional significance, most likely of epigenetic
nature [56]. Admittedly highly speculative, one possible scenario may be that the hypoxic
micro-environment of the 3rd sub-ventricular zone triggers tumorigenic epigenetic alterations
in our RG cells, whose transcription and epigenetic landscapes represent the early stages of
primitive neuro-ectoderm differentiation [15]. The presence of RG—BTIC markers such as
SOX2, Vimentin, Nestin, and of BTIC marker OCT3/4 also suggest that our CNS-PNETs might
arise directly from the orthotopically transplanted RG, or from its early progeny, which, based
on our hypothesis, would undergo transformation to become BTICs, thus initiating tumorigen-
esis. It is also conceivable that the MYCC onco-protein plays a central role in this process.
MYCC is evolutionarily conserved [57], and its role as a signal transducer linking the extra-
cellular and intracellular domains may track back to single-cell organisms [58]. It is a highly
Fig 6. Expression of TP53, YB1 and MDM2 in our CNS-PNET model tumors A. TP53 40x, insert- 5X digital (LCAS-R) B: TP53 40x,
insert- 5X digital (LCAS-R-12 weeks post-injection) C: TP53 40x, insert- 5X digital (LC26-R-12 weeks post-injection) D: YB-1 40X, insert- 5X
digital (LCAS-R-12 weeks post-injection) E: MDM2 5x, F: MDM2 40x, (LCAS-R-12 weeks post-injection) TU-tumor; P-parenchyma; V-
ventricle.
doi:10.1371/journal.pone.0173106.g006
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multifunctional transcription factor [59–61], which acts as a general amplifier in the regions of
open chromatin at the time of MYCC activation [62]. Deregulated expression of MYCC in
cancer commonly occurs through constitutive activation of upstream signaling pathways. [63].
Overexpression of MYCC enhances HIF-1 α accumulation under hypoxic conditions [64].
Moreover, the dysregulated expression of MYCC synergizes with HIFs to form the tumor met-
abolic phenotype that is described as aerobic glycolysis [65], and to promote MYCC -induced
anchorage-independent growth and cell proliferation [64]. MYCC is essential not only for
tumor initiation and progression but also for tumor maintenance [66–72]. As with HIFs, the
dysregulated expression of MYCC could also synergize with the loss of the tumor suppressor
TP53, which in turn would induce cellular proliferation and tumorigenesis [73], particularly in
NSCs [74]. A recently published study revealed significant association of TP53 mutation and
MYC gene family up-regulation at relapse in medulloblastoma patients [75].
Despite the fact that altered expression of the MYCC oncogene occurs in ~70% of human
tumors, the specific mechanism that affects MYCC in each tumor type is still largely unknown
[76, 32]. Moreover, a comprehensive assessment of the MYCC target genes in different brain
tumors is also missing. Such a comprehensive identification of MYCC target genes might
constitute the basis for a better understanding of the mechanisms underlying MYCC-driven
tumorigenesis, and for development of new therapeutic strategies. Our model might be
exploited to facilitate such analyses and to decode PNET’s specific mechanism of MYCC dys-
regulation. Lastly, it might also be used to validate experimental drugs targeting MYCC, which
are likely to aid in combined therapy regimens [77–79].
Fundamental questions remain regarding the mechanisms by which hypoxia induces
genetic alterations (such as TP53 mutation), controls cell proliferation, and contributes to the
altered metabolic phenotype of cancer cells. Furthermore, it remains to be determined if hyp-
oxia is indeed responsible for triggering tumorigenesis in our model, which will be the object
of future investigations. These studies are likely to prove relevant to the broad range of tumors
that are affected by hypoxia.
Conclusions
In conclusion, we showed that the presence of stabilized HIF-1 α and HIF-2 α, up-regulation
of MYCC, and accumulation of stabilized p53 constitute hallmarks of CNS-PNET in our
model, and we speculate that such alterations might represent the basis for tumorigenesis in
this tumor model. We also put forth the hypothesis that these three events might be interde-
pendent, and that hypoxia might be one of the initiating micro- environmental factors under-
lying tumorigenesis in our CNS-PNET model.
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